Objective of the Review: to analyse current American and European recommendations and to present modern approaches to prescription of antithrombotic medicines to patients with atrial fibrillation during percutaneous coronary interventions.
Key Points. Key results of international clinical studies to compare safety and efficiency of triple and double antithrombotic therapy (ATT) are presented. Addressed are the current clinical opinions triggering questions asked by practicians as regards prescription and later withdrawal of acetylsalicylic acid (ASA), use of Clopidogrel and novel antiaggregants in double and triple ATT.
Conclusion. Rational use of both triple (oral anticoagulant (OAC) + Clopidogrel + ASA) and double ATT (OAC+ P2Y12 platelet receptor inhibitor). The triple therapy duration should be reduced as much as possible; all recommendations give preference to double therapy, and in a number of consensus papers, double therapy is a therapy of choice for the majority of patients.
Contributions: Barbarash, O.L. — general concept, text preparation and final review; Kashtalap, V.V. — analytical comparison of the current American and European clinical recommendations.
Conflict of interest: The authors declare that they do not have any conflict of interests.
O.L. Barbarash (Corresponding author) — Scientific and Research Institute of Complex Cardiovascular Problems; 6 Sosnovyi Blvd., Kemerovo, Russian Federation 650002. Federal State-Funded Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation; 22A Voroshilova Str., Kemerovo, Russian Federation 650056. eLIBRARY.RU SPIN: 5373-7620. ORCID: https://orcid.org/0000-0002-4642-3610. E-mail: email@example.com
V.V. Kashtalap — Scientific and Research Institute of Complex Cardiovascular Problems; 6 Sosnovyi Blvd., Kemerovo, Russian Federation 650002. eLIBRARY.RU SPIN: 8816-7409. ORCID: https://orcid.org/0000-0003-3729-616Х. E-mail: firstname.lastname@example.org